Bavarian Nordic A/S
XMUN:BV3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bavarian Nordic A/S
XMUN:BV3
|
DK |
|
E
|
eMan as
PSE:EMAN
|
CZ |
Intrinsic Value
The intrinsic value of Bavarian Nordic A/S (BV3) under the Base Case is 25.21 EUR per share. Compared with the current market price of 32.44 EUR, the stock appears Overvalued by 22% .
The intrinsic value is the average of valuations using the DCF method and multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Bavarian Nordic A/S Does
Bavarian Nordic is a vaccine company that develops, makes, and sells vaccines for infectious diseases. Its best-known products are vaccines for smallpox and mpox, rabies, and tick-borne encephalitis, along with a few other travel and specialty vaccines. It also works on vaccine candidates for other diseases and immune-related medicines, but its core business is finished vaccines rather than general drug development.
- Headquarters
- Denmark DK
- Employees
- 1 861
- IPO date
- Nov 2, 1998
Revenue & Expenses Breakdown
Bavarian Nordic A/S
Earnings Waterfall
Bavarian Nordic A/S
The intrinsic value for Bavarian Nordic A/S (BV3) under the Base Case is 25.21 EUR.
Compared with the current market price of 32.44 EUR, the stock appears Overvalued by 22% .